PD-L1 testing in first-line treatment of NSCLC

In this interview, Benjamin Besse, MD, PhD, Institut Gustave Roussy, Paris, France, addresses challenges associated with PD-L1 testing, and advocates for reflex PD-L1 testing at the time of diagnosis of non-small cell lung cancer (NSCLC). Reflex testing for EGFR mutations, ALK rearrangements and PD-L1 would help treating oncologists to optimise treatment decisions and avoid delays in treatment. Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
Share this video